Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats

  title={Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats},
  author={Tae-Heon Kim and Jong-woo Jeong and Ji-Hye Song and Kyeong-Ryoon Lee and Sunjoo Ahn and Sung-hoon Ahn and Sungsub Kim and Tae-Sung Koo},
  journal={Archives of Pharmacal Research},
Abstract We characterized the pharmacokinetics of enzalutamide, a novel anti-prostate cancer drug, in rats after intravenous and oral administration in the dose range 0.5–5 mg/kg. Tissue distribution, liver microsomal stability, and plasma protein binding were also examined. After intravenous injection, systemic clearance, volumes of distribution at steady state (Vss), and half-life (T½) remained unaltered as a function of dose, with values in the ranges of 80.4–86.3 mL/h/kg, 1020–1250 mL/kg… Expand
Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats
Tafamidis undergoes minimal first-pass metabolism, distributes mostly in the liver and plasma, and appears to be eliminated primarily via biliary excretion. Expand
Synthesis and Evaluation of F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16b-F-Fluoro-5a-Dihydrotestosterone
16b-F-fluoro-5a-dihydrotestosterone (F-FDHT) is a radiopharmaceutical that has been investigated as a diagnostic agent for the assessment of androgen receptor (AR) density in prostate cancer usingExpand
Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16β-18F-Fluoro-5α-Dihydrotestosterone
18F-enzalutamide shows higher tumor uptake and better metabolic stability than 18F-FDHT and thus seems to have more favorable properties for imaging of AR with PET, but further evaluation in other oncologic animal models and patients is warranted to confirm these results. Expand
Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy
A multifunctional nanocarrier constructed here could accomplish controlled Enz release and serve as an intravenous therapy platform for CRPC and exhibited an enhanced cancer-targeting ability and alleviated the side effects of Enz in vivo. Expand
A Validated Stability Indicating RP-HPLC Method Development for Anticancer Drug Enzalutamide in Bulk and Pharmaceuticals
A reproducible stability-indicating Reverse Phase-HPLC technique for the quantification of Enzalutamide in in pharmaceuticals was developed and validated. Chromatography was done on Inertsil ODS-C18Expand
Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
APA, ENZA, and DARO should be considered the new standard drugs for treating nmCRPC with substantial improvements in metastasis-free survival (MFS) and OS in phase III randomized clinical trials. Expand
Dose considerations for anti‐cancer drugs in metastatic prostate cancer
Drug‐specific issues that may be associated with unexpected or unrecognized variations in drug systemic exposure despite the use of protocol doses are reviewed. Expand
Chromatographic Methods for Determination of Drugs Used in Prostate Cancer in Biological and Pharmacological Samples
  • Cafer Saka
  • Medicine
  • Critical reviews in analytical chemistry
  • 2019
This review article contains a summary of analyzes performed by chromatographic methods used for the determination of abiraterone acetate, bicalutamide, cabazitaxel, docetaxel and enzalutamide used in prostate cancer applications in biological and pharmacological samples. Expand
Quality by Design–Applied Liquid Chromatography-Tandem Mass Spectrometry Determination of Enzalutamide Anti-Prostate Cancer Therapy Drug in Spiked Plasma Samples
The Quality by Design–finalised conditions for a method that uses liquid chromatography-tandem mass spectrometry for the determination of concentration of enzalutamide (ENZ), an atypical anticancer drug, in a drug formulation and in spiked plasma samples are presented. Expand
Synthesis and biological activities of novel trifluoromethylpyridine amide derivatives containing sulfur moieties
  • S. X. Guo, F. He, A. Dai, R. F. Zhang, S. H. Chen, J. Wu
  • Chemistry
  • 2020
A series of trifluoromethylpyridine amide derivatives containing sulfur moieties (thioether, sulfone and sulfoxide) was designed and synthesized. Their antibacterial activities against XanthomonasExpand


Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats
To characterise the pharmacokinetics of lurasidone, a new atypical anti-psychotic drug, in rats after intravenous and oral administration at dose range 0.5–2.5 and 2.5-10 mg/kg, lurasidsone showed dose-independent Pharmacokinetics and appeared to be primarily eliminated by its metabolism. Expand
Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats
After intravenous injection, terminal half-life, systemic clearance, and steady state volumes of distribution remained unaltered as a function of dose with values in the range 3.01–3.53 h, 221–241 mL/h/kg and 702–732 mL/kg, respectively. Expand
Increased survival with enzalutamide in prostate cancer after chemotherapy.
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy, and was shown with respect to all secondary end points. Expand
Quantitative determination of enzalutamide, an anti-prostate cancer drug, in rat plasma using liquid chromatography-tandem mass spectrometry, and its application to a pharmacokinetic study.
This analytical method could be successfully applied to the pharmacokinetic study of enzalutamide in rats and demonstrated a linear standard curve over a concentration range of 0.001-1 µg/mL and an intra- and inter-assay precision of 2.7 and 5.1%. Expand
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
The results of this phase 1-2 trial validate in man preclinical studies implicating sustained androgen-receptor signalling as a driver in this disease. Expand
Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
Enzalutamide is a novel second generation antiandrogen that has been demonstrated to significantly improve survival in men with metastatic CRPC in several clinical trials and its limitations for treatment of CRPC are discussed. Expand
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade. Expand
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer. Expand
Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance
  • K. Pang, M. Rowland
  • Chemistry, Medicine
  • Journal of Pharmacokinetics and Biopharmaceutics
  • 2005
Although both models predict similar hepatic drug clearances under a variety of conditions, marked differences between them become apparent in their predictions of the influence of changes in the determinants of drug clearance on various pharmacokinetic parameters. Expand
Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection.
It is observed that, although flutamide and cyproterone acetate blocked androgen-induced gene expression, they failed to inhibit DHT protection against apoptotic insults in cultured hippocampal neurons, suggesting a role for AR in the agonist effects of antiandrogens. Expand